Proxygen
Biotechnology ResearchView the employees at
Proxygen-
Tamara Halter Data Scientist at Proxygen
-
Vienna, Vienna, Austria
-
Top 10%
Styliani Karagiorgou Research technician, Proxygen-
Austria
-
Rising Star
Sophie Bauer Staff Scientist bei Proxygen-
Vienna, Vienna, Austria
-
Rising Star
Milica Vunjak Targeted protein degradation | CRISPR screens | Drug discovery-
Austria
-
Top 10%
Overview
Proxygen is a Vienna-based startup that develops therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase. Consequently, the target protein is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete, targeted and selective elimination. This outlines a clear avenue towards targeting otherwise undruggable proteins and is therefore seen as one of the most promising innovations of the last decades.
-